Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.

<h4>Background</h4>We recently reported a relationship between plasma levels of cystatin C and incidence of the metabolic syndrome (MetS) among the first 2,369 subjects who participated in the re-examination study of the population-based Malmö and Diet Cancer Cardiovascular cohort (MDC-C...

Full description

Bibliographic Details
Main Authors: Martin Magnusson, John Molvin, Gunnar Engström, Patrik Svensson-Färbom, Margaretha Persson, Anders Christensson, Peter Nilsson, Olle Melander
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155735&type=printable
_version_ 1826584044607897600
author Martin Magnusson
John Molvin
Gunnar Engström
Patrik Svensson-Färbom
Margaretha Persson
Anders Christensson
Peter Nilsson
Olle Melander
author_facet Martin Magnusson
John Molvin
Gunnar Engström
Patrik Svensson-Färbom
Margaretha Persson
Anders Christensson
Peter Nilsson
Olle Melander
author_sort Martin Magnusson
collection DOAJ
description <h4>Background</h4>We recently reported a relationship between plasma levels of cystatin C and incidence of the metabolic syndrome (MetS) among the first 2,369 subjects who participated in the re-examination study of the population-based Malmö and Diet Cancer Cardiovascular cohort (MDC-CC-re-exam). In this study we aimed to replicate these results and also investigate if cystatin C was causally associated with MetS and diabetes.<h4>Methods</h4>We estimated the effect size of the strongest GWAS derived cystatin C SNP (major allele of rs13038305) on plasma cystatin C in the now completed MDC-CC-re-exam (n = 3,734) and thereafter examined the association between plasma cystatin C (403 cases of diabetes and 2665 controls) as well as rs13038305 (235 cases and 2425 controls) with incident diabetes. The association of rs13038305 and incident MetS (511 cases of MetS and 1980 controls) was similarly investigated in the whole MDC-CC-re-exam. We also attempted to replicate our previously shown association of cystatin C with incident MetS in subjects from the MDC-CC-re-exam (147 cases and 711 controls) that were not included in our previous report.<h4>Results</h4>In the entire MDC-CC-re-exam, each copy of the major allele of rs13038305 was associated with approximately 0.30 standard deviation (SD) higher plasma concentration of cystatin C (β = 0.33, p = 4.2E-28) in age and sex adjusted analysis. Cystatin C in plasma was not associated with incident diabetes after adjustment for known diabetes risk factors (OR per 1 SD increment 0.99 (0.86-1.13), p = 0.842). In the replication cohort of MDC-CC-re-exam, the OR (95% CI) for incident MetS in subjects belonging to quartiles 1, 2, 3 and 4 of plasma cystatin C levels was 1.00 (reference), 1.21 (0.70-2.07), 1.62 (0.95-2.78) and 1.72 (1.01-2.93) (ptrend = 0.026) in age and sex adjusted analysis. In the entire MDC-CC-re-exam the odds ratio for incident MetS and diabetes per copy of the major rs13038305 allele was 1.13, (0.95-1.34), p = 0.160 and 1.07, 95% CI 0.89-1.30, p = 0.478, respectively.<h4>Conclusion</h4>We were able to replicate our previously shown association between high levels of cystatin C and increased risk of future development of MetS. However, a causal involvement of cystatin C in the etiology of MetS or diabetes seems unlikely since genetic elevation of plasma cystatin C was not significantly related to incidence of these diseases.
first_indexed 2024-12-22T09:45:36Z
format Article
id doaj.art-3b6df2f111e440968f3789db67636681
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2025-03-14T15:31:30Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-3b6df2f111e440968f3789db676366812025-02-25T05:36:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015573510.1371/journal.pone.0155735Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.Martin MagnussonJohn MolvinGunnar EngströmPatrik Svensson-FärbomMargaretha PerssonAnders ChristenssonPeter NilssonOlle Melander<h4>Background</h4>We recently reported a relationship between plasma levels of cystatin C and incidence of the metabolic syndrome (MetS) among the first 2,369 subjects who participated in the re-examination study of the population-based Malmö and Diet Cancer Cardiovascular cohort (MDC-CC-re-exam). In this study we aimed to replicate these results and also investigate if cystatin C was causally associated with MetS and diabetes.<h4>Methods</h4>We estimated the effect size of the strongest GWAS derived cystatin C SNP (major allele of rs13038305) on plasma cystatin C in the now completed MDC-CC-re-exam (n = 3,734) and thereafter examined the association between plasma cystatin C (403 cases of diabetes and 2665 controls) as well as rs13038305 (235 cases and 2425 controls) with incident diabetes. The association of rs13038305 and incident MetS (511 cases of MetS and 1980 controls) was similarly investigated in the whole MDC-CC-re-exam. We also attempted to replicate our previously shown association of cystatin C with incident MetS in subjects from the MDC-CC-re-exam (147 cases and 711 controls) that were not included in our previous report.<h4>Results</h4>In the entire MDC-CC-re-exam, each copy of the major allele of rs13038305 was associated with approximately 0.30 standard deviation (SD) higher plasma concentration of cystatin C (β = 0.33, p = 4.2E-28) in age and sex adjusted analysis. Cystatin C in plasma was not associated with incident diabetes after adjustment for known diabetes risk factors (OR per 1 SD increment 0.99 (0.86-1.13), p = 0.842). In the replication cohort of MDC-CC-re-exam, the OR (95% CI) for incident MetS in subjects belonging to quartiles 1, 2, 3 and 4 of plasma cystatin C levels was 1.00 (reference), 1.21 (0.70-2.07), 1.62 (0.95-2.78) and 1.72 (1.01-2.93) (ptrend = 0.026) in age and sex adjusted analysis. In the entire MDC-CC-re-exam the odds ratio for incident MetS and diabetes per copy of the major rs13038305 allele was 1.13, (0.95-1.34), p = 0.160 and 1.07, 95% CI 0.89-1.30, p = 0.478, respectively.<h4>Conclusion</h4>We were able to replicate our previously shown association between high levels of cystatin C and increased risk of future development of MetS. However, a causal involvement of cystatin C in the etiology of MetS or diabetes seems unlikely since genetic elevation of plasma cystatin C was not significantly related to incidence of these diseases.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155735&type=printable
spellingShingle Martin Magnusson
John Molvin
Gunnar Engström
Patrik Svensson-Färbom
Margaretha Persson
Anders Christensson
Peter Nilsson
Olle Melander
Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.
PLoS ONE
title Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.
title_full Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.
title_fullStr Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.
title_full_unstemmed Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.
title_short Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.
title_sort cystatin c and risk of diabetes and the metabolic syndrome biomarker and genotype association analyses
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155735&type=printable
work_keys_str_mv AT martinmagnusson cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT johnmolvin cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT gunnarengstrom cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT patriksvenssonfarbom cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT margarethapersson cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT anderschristensson cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT peternilsson cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses
AT ollemelander cystatincandriskofdiabetesandthemetabolicsyndromebiomarkerandgenotypeassociationanalyses